ERAS — Erasca, Inc. Stock Price, Chart & AI Report

Negative Jul 15, 2026 • 16:52 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

Rosen Law Firm is reminding investors who purchased Erasca, Inc. common stock between January 14, 2025 and April 26, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes.

ERAS securities class action false statements oncology drug lead plaintiff deadline investor compensation ERAS-0015

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret disputes, resulting in investor damages.

Negative Jul 15, 2026 • 02:42 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti, LLC announces a class action securities lawsuit against Erasca, Inc. for investors who purchased shares between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca and its executives failed to disclose material information, including that preclinical data for ERAS-0015 was based on improper comparisons and placed the company at risk of patent violations. The application deadline to request lead plaintiff status is August 10, 2026.

ERAS class action lawsuit securities fraud material omissions ERAS-0015 patent violations RAS-mutated solid tumors

Sentiment note

The company is facing a securities class action lawsuit alleging failure to disclose material information regarding its ERAS-0015 product, improper data comparisons, and patent/trade secret violation risks. These allegations of corporate misconduct and regulatory violations warrant a negative sentiment.

Negative Jul 14, 2026 • 13:56 UTC GlobeNewswire Inc. • Suewallst

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in Erasca, Inc. Lawsuit - ERAS

Erasca, Inc. faces a securities class action lawsuit alleging that CEO Jonathan Lim and CFO David Chacko certified misleading statements about the ERAS-0015 drug trial while the company raised $258.8 million from investors. The stock collapsed 53.9% after disclosures revealed patent infringement allegations and a patient death. The lead plaintiff deadline is set for August 10, 2026.

ERAS securities class action misleading statements patent infringement Sarbanes-Oxley certification Section 20(a) liability lead plaintiff stock collapse

Sentiment note

Company faces securities fraud allegations involving senior executives certifying false statements about clinical trial data. Stock declined 53.9% following corrective disclosures of patent infringement and patient death in trials. The company raised $258.8 million while allegedly concealing material information from investors.

Positive Jul 14, 2026 • 03:10 UTC GlobeNewswire Inc. • Na

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an upsized public offering of 31.4 million shares at $17.50 per share, generating approximately $550 million in gross proceeds. The offering is expected to close on July 15, 2026, with proceeds to be used for R&D of product candidates and general corporate purposes.

ERAS public offering precision oncology RAS/MAPK pathway capital raise clinical-stage common stock

Sentiment note

The company successfully upsized its public offering and secured $550 million in gross proceeds at $17.50 per share, demonstrating investor confidence. The capital raise provides substantial funding for R&D of its oncology pipeline, which is positive for a clinical-stage company's ability to advance its drug candidates and achieve its mission in precision oncology.

Negative Jul 13, 2026 • 10:50 UTC GlobeNewswire Inc. • Robbins Geller Rudman & Dowd Llp

INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

A class action lawsuit has been filed against Erasca, Inc. alleging that the company and its executives made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims preclinical data was based on improper comparisons to Revolution Medicines and lacked reasonable basis. Following disclosure of a patent infringement letter from Revolution Medicines and adverse Phase I clinical data including a patient death, Erasca's stock fell approximately 59% in total.

ERAS RVMD RVMDW class action lawsuit securities fraud ERAS-0015 patent infringement clinical trial data

Sentiment note

Company faces securities fraud class action lawsuit alleging false statements about drug candidate efficacy, patent infringement claims from competitor, adverse clinical trial results including patient death, and significant stock price decline of approximately 59%.

Negative Jul 12, 2026 • 21:53 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, LEADING INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

Rosen Law Firm is urging investors who purchased Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026 to join a securities class action lawsuit before the August 10, 2026 lead plaintiff deadline. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes.

ERAS securities class action false statements oncology drug lead plaintiff deadline investor compensation patent disputes

Sentiment note

The company is accused of making false and misleading statements about its lead drug candidate ERAS-0015, including improper comparisons to competitors and undisclosed patent/trade secret disputes. A securities class action lawsuit has been filed against the company and its executives, indicating potential investor losses.

Negative Jul 11, 2026 • 12:49 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

ERAS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. Investors who purchased ERAS securities between January 14, 2025 and April 26, 2026 can seek lead plaintiff status by August 10, 2026.

ERAS RVMD RVMDW securities fraud class action lawsuit patent infringement trade secret misappropriation clinical trial death

Sentiment note

Company faces federal securities class action lawsuit alleging false and misleading statements about drug candidate ERAS-0015. Disclosed patent infringement allegations, improper data comparisons, and a patient death in clinical trials, resulting in a 54% stock price decline over two trading days from $21.49 to $9.90 per share.

Negative Jul 10, 2026 • 19:07 UTC GlobeNewswire Inc. • Robbins Llp

Robbins LLP Urges ERAS Stockholders to Contact the Firm for Information About the Class Action Against Erasca, Inc.

A class action lawsuit has been filed against Erasca, Inc. (NASDAQ: ERAS) on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026. Shareholders allege that Erasca failed to disclose risks related to patent and trade secret violations regarding its ERAS-0015 drug candidate. The allegations emerged after Revolution Medicines sent a cease-and-desist letter claiming patent infringement and trade secret misappropriation. Following the disclosure on April 27, 2026, Erasca's stock price fell from $21.49 to $19.15 per share.

ERAS RVMD RVMDW class action lawsuit patent infringement trade secret misappropriation securities fraud clinical-stage oncology

Sentiment note

The company faces a class action lawsuit alleging material non-disclosure of patent and trade secret risks. A competitor's cease-and-desist letter regarding alleged infringement and improper data comparisons triggered a significant stock price decline of approximately 10.9%, indicating serious legal and reputational damage.

Negative Jul 9, 2026 • 23:50 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

Rosen Law Firm is soliciting investors who purchased Erasca, Inc. (NASDAQ: ERAS) stock between January 14, 2025 and April 26, 2026 to join a securities class action lawsuit. The lawsuit alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate ERAS-0015, including improper comparisons to a competing drug and undisclosed patent disputes. The lead plaintiff deadline is August 10, 2026.

ERAS securities class action false and misleading statements oncology drug ERAS-0015 patent disputes investor damages lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging violations of federal securities laws through false and misleading statements about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret disputes. These allegations resulted in investor damages when the truth entered the market.

Negative Jul 7, 2026 • 19:55 UTC GlobeNewswire Inc. • Holzer & Holzer, Llc

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BitGo Holdings, Inc. (BTGO), Erasca, Inc. (ERAS), and First Solar, Inc. (FSLR) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for three shareholder class action lawsuits. BitGo Holdings faces allegations of false statements regarding digital asset price risks (deadline: August 7, 2026). Erasca is accused of material misstatements about ERAS-0015 between January 2025 and April 2026 (deadline: August 10, 2026). First Solar faces claims of failing to disclose material facts about U.S. tariff policy impacts between February 2025 and February 2026 (deadline: August 24, 2026).

BTGO ERAS FSLR shareholder class action lead plaintiff securities litigation material misstatements disclosure failures

Sentiment note

Company is defendant in class action lawsuit alleging materially false/misleading statements and failure to disclose material facts regarding ERAS-0015 during specified period.

Negative Jul 6, 2026 • 20:43 UTC GlobeNewswire Inc. • Hagens Berman Shareholder Rights Law Firm

Erasca (ERAS) Faces Securities Class Action After Stock Declines 48% on Drug Safety and IP Concerns-- HBSS

Erasca Inc. (ERAS) faces a securities class action lawsuit after its stock plummeted 48% following disclosures of a patient death linked to its experimental drug ERAS-0015 and patent infringement accusations from Revolution Medicines. The lawsuit alleges Erasca misled investors about the drug's safety profile and intellectual property protection through improper comparisons with competing therapies.

ERAS RVMD RVMDW securities class action patent infringement drug safety ERAS-0015 pan-RAS molecular glue

Sentiment note

Stock declined 48% ($9.25) following disclosure of patient death associated with ERAS-0015 and patent infringement allegations from Revolution Medicines. Company faces securities class action lawsuit for allegedly misleading investors about drug safety and IP protection. Over $2.8 billion in market capitalization was wiped out.

Negative Jul 3, 2026 • 23:49 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Erasca, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ERAS

A securities class action lawsuit has been filed against Erasca, Inc. for allegedly making false and misleading statements about its lead oncology drug candidate ERAS-0015. The company and its executives are accused of improperly comparing their drug to a competitor's candidate while failing to disclose patent and trade secret disputes. Investors who purchased Erasca stock between January 14, 2025 and April 26, 2026 may be eligible for compensation, with a lead plaintiff deadline of August 10, 2026.

ERAS securities class action false statements oncology drug ERAS-0015 patent dispute investor compensation lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret disputes. These allegations suggest potential fraud and regulatory violations that resulted in investor losses.